Helle H. N.
- Country
- Denmark
- Department
- 7100: Neurologisk Afdeling, Sklerosekliniken
Research Overview
- Efficacy and Safety of Remibrutinib in Patients with Secondary Progressive Multiple Sclerosis: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study
- Long-term Safety, Tolerability, and Efficacy Evaluation of Ofatumumab in Patients with Relapsing Multiple Sclerosis: An Open-label Extension Study
Data & Insights
Has run more than one trial at 52 of 223 partner sites.
Specializations
Neurological Conditions
The investigator specializes in the treatment and research of relapsing multiple sclerosis (RMS), focusing on innovative therapeutic approaches for managing this chronic neurological condition.
- Multiple Sclerosis Management
- Autoimmune Neurological Disorders
- Long-term Disease Control
Their clinical interests extend to evaluating the prolonged efficacy and safety profiles of novel therapeutic agents in neurological conditions.
Therapeutic Development
Primary focus includes investigating monoclonal antibody treatments for neurological disorders, with particular attention to long-term safety and tolerability assessment.
- Immunomodulatory Therapies
- Subcutaneous Administration Methods
- Extended Treatment Protocols
The investigator explores maintenance therapy approaches in chronic neurological conditions requiring ongoing treatment.
Clinical Monitoring
Expertise in conducting long-term safety evaluations and monitoring the sustained effectiveness of treatments in neurological disorders.
- Treatment Safety Assessment
- Therapeutic Tolerability
- Extended Clinical Observation
Their work encompasses comprehensive monitoring of treatment responses in patients with chronic neurological conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.